ABSTRACT
Patients with severe mental illness, such as schizophrenia, depression or bipolar disorder, are more likely to be overweight and to suffer from dyslipidaemia, diabetes or cardiovascular disease. Unhealthy lifestyles, including poor diet and sedentary behaviour, but also pharmacotherapy contribute to the adverse risk profile. This article reviews the epidemiology and pharmacodynamics of metabolic abnormalities in psychiatric patients treated with antipsychotics, focusing on substance-specific differences.
Subject(s)
Antipsychotic Agents/adverse effects , Metabolic Diseases/chemically induced , Metabolic Diseases/epidemiology , Germany , Humans , Prevalence , Risk Assessment , Risk FactorsSubject(s)
Antimanic Agents/therapeutic use , Depressive Disorder/drug therapy , Lithium Carbonate/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Thiophenes/therapeutic use , Aged , Drug Therapy, Combination , Duloxetine Hydrochloride , Female , Hospitalization , Humans , Male , OutpatientsABSTRACT
INTRODUCTION: Abnormalities on acute magnetic resonance imaging predict outcome in minor stroke and transient ischaemic attack patients. We hypothesised that noncontrast computed tomography and computed tomography angiography findings in minor stroke and transient ischaemic attack patients would also predict functional outcome. METHODS: We analysed consecutive patients with a transient ischaemic attack or a minor stroke with an National Institute of Health Stroke Scale